Velnacrine maleate (BioDeep_00000659526)

   


代谢物信息卡片


Velnacrine maleate

化学式: C17H18N2O5 (330.1215658)
中文名称: 马来酸维吖啶
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: C1CC(C2=C(C3=CC=CC=C3N=C2C1)N)O.C(=CC(=O)O)C(=O)O
InChI: 2-1-

描述信息

D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D002800 - Cholinesterase Inhibitors
C471 - Enzyme Inhibitor > C47792 - Acetylcholinesterase Inhibitor
D004791 - Enzyme Inhibitors

同义名列表

2 个代谢物同义名

Velnacrine maleate; UNII:4401EF6U24



数据库引用编号

7 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有:

  • PubMed: 来源于PubMed文献库中的文献信息,我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表,这个列表按照代谢物同时出现的文献数量降序排序,取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘,得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序,取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中,存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称,可以跳转到相关代谢物的信息页面。



文献列表

  • A S Silva-Herdade, C Saldanha. Effects of acetylcholine on an animal mode of inflammation. Clinical hemorheology and microcirculation. 2013; 53(1-2):209-16. doi: 10.3233/ch-121646. [PMID: 23187452]
  • Shuai Qian, Siu Kwan Wo, Zhong Zuo. Pharmacokinetics and brain dispositions of tacrine and its major bioactive monohydroxylated metabolites in rats. Journal of pharmaceutical and biomedical analysis. 2012 Mar; 61(?):57-63. doi: 10.1016/j.jpba.2011.11.025. [PMID: 22196801]
  • José Pedro Almeida, Filomena Almeida Carvalho, Teresa Freitas, Carlota Saldanha. Modulation of hemorheological parameters by the erythrocyte redox thiol status. Clinical hemorheology and microcirculation. 2008; 40(2):99-111. doi: 10.3233/ch-2008-1120. [PMID: 19029635]
  • A S Silva, C Saldanha, J Martins e Silva. Effects of velnacrine maleate in the leukocyte-endothelial cell interactions in rat cremaster microcirculatory network. Clinical hemorheology and microcirculation. 2007; 36(3):235-46. doi: NULL. [PMID: 17361025]
  • I Aparicio, M Callejón, M A Bello, J C Jiménez, A Guiraúm. Spectrofluorimetric determination of velnacrine in human serum and urine. Farmaco (Societa chimica italiana : 1989). 2003 Dec; 58(12):1257-61. doi: 10.1016/j.farmac.2003.07.007. [PMID: 14630236]
  • I Aparicio, M Callejón, J C Jiménez, M A Bello, A Guiraúm. Electrochemical oxidation at carbon paste electrode of tacrine and 1-hydroxytacrine and differential pulse voltammetric determination of tacrine in pharmaceuticals and human urine. The Analyst. 2000 Nov; 125(11):2016-9. doi: 10.1039/b005874m. [PMID: 11193091]
  • K Laine, S Palovaara, P Tapanainen, P Manninen. Plasma tacrine concentrations are significantly increased by concomitant hormone replacement therapy. Clinical pharmacology and therapeutics. 1999 Dec; 66(6):602-8. doi: 10.1053/cp.1999.v66.103404001. [PMID: 10613616]
  • D M Wood, J M Ford, C J Roberts. Variability in the plasma protein binding of velnacrine (1-hydroxy tacrine hydrochloride). A potential agent for Alzheimer's disease. European journal of clinical pharmacology. 1996; 50(1-2):115-9. doi: 10.1007/s002280050078. [PMID: 8739821]
  • W J Jackson, J J Buccafusco, A V Terry, D J Turk, D K Rush. Velnacrine maleate improves delayed matching performance by aged monkeys. Psychopharmacology. 1995 Jun; 119(4):391-8. doi: 10.1007/bf02245854. [PMID: 7480518]
  • S al Casey, D Brewster, C Viau, D Acosta. Effect of glutathione depletion and oxidative stress on the in vitro cytotoxicity of velnacrine maleate. Toxicology letters. 1995 Apr; 76(3):257-65. doi: 10.1016/0378-4274(95)80011-2. [PMID: 7762013]
  • D B Haughey, C A McNaney, M S Collis, R R Brown, P H Siedlik, L Balogh, P M Klockowski. Simultaneous determination of tacrine and 1-hydroxy-, 2-hydroxy-, and 4-hydroxytacrine in human plasma by high-performance liquid chromatography with fluorescence detection. Journal of pharmaceutical sciences. 1994 Nov; 83(11):1582-5. doi: 10.1002/jps.2600831113. [PMID: 7891279]
  • W D Hooper, W F Pool, T F Woolf, J Gal. Stereoselective hydroxylation of tacrine in rats and humans. Drug metabolism and disposition: the biological fate of chemicals. 1994 Sep; 22(5):719-24. doi: . [PMID: 7835223]
  • R G Turcan, D Hillbeck, T E Hartley, P J Gilbert, R A Coe, J A Troke, C W Vose. Disposition of [14C]velnacrine maleate in rats, dogs, and humans. Drug metabolism and disposition: the biological fate of chemicals. 1993 Nov; 21(6):1037-47. doi: NULL. [PMID: 7905382]
  • S Hardiman, K Miller, M Murphy. Clinical trials with velnacrine: (PROPP) the physician reference of predicted probabilities--a statistical model for the estimation of hepatotoxicity risk with velnacrine maleate. Acta neurologica Scandinavica. Supplementum. 1993; 149(?):46-52. doi: 10.1111/j.1600-0404.1993.tb04255.x. [PMID: 8128839]
  • N R Cutler, J J Sramek, M F Murphy, R J Nash. Implications of the study population in the early evaluation of anticholinesterase inhibitors for Alzheimer's disease. The Annals of pharmacotherapy. 1992 Sep; 26(9):1118-22. doi: 10.1177/106002809202600914. [PMID: 1421679]
  • C A Truman, J M Ford, C J Roberts. Comparison of the chromatographic characteristics of metabolites of tacrine hydrochloride in human serum and urine with those of in vitro metabolic products from hepatic microsomes. Biochemical pharmacology. 1991 Jul; 42(4):956-9. doi: 10.1016/0006-2952(91)90061-9. [PMID: 1867652]
  • S K Puri, I Ho, R Hsu, H B Lassman. Multiple dose pharmacokinetics, safety, and tolerance of velnacrine (HP 029) in healthy elderly subjects: a potential therapeutic agent for Alzheimer's disease. Journal of clinical pharmacology. 1990 Oct; 30(10):948-55. doi: 10.1002/j.1552-4604.1990.tb03576.x. [PMID: 2229455]
  • N R Cutler, M F Murphy, R J Nash, P L Prior, D M De Luna. Clinical safety, tolerance, and plasma levels of the oral anticholinesterase 1,2,3,4-tetrahydro-9-aminoacridin-1-oL-maleate (HP 029) in Alzheimer's disease: preliminary findings. Journal of clinical pharmacology. 1990 Jun; 30(6):556-61. doi: 10.1002/j.1552-4604.1990.tb03620.x. [PMID: 2355106]
  • S K Puri, R S Hsu, I Ho, H B Lassman. The effect of food on the bioavailability of velnacrine (HP 029) in healthy elderly men: a potential Alzheimer agent. Journal of clinical pharmacology. 1989 Oct; 29(10):956-60. doi: 10.1002/j.1552-4604.1989.tb03261.x. [PMID: 2592587]
  • R S Hsu, E M DiLeo, S M Chesson, D B Ellis, J K Wichmann. Determination of velnacrine in plasma and urine by high-performance liquid chromatography. Journal of chromatography. 1989 Sep; 494(?):347-53. doi: 10.1016/s0378-4347(00)82687-0. [PMID: 2584332]
  • L Ekman, B Lindström, P Roxin. Determination of tacrine and its 1-hydroxy metabolite in plasma using column liquid chromatography with ultraviolet detection. Journal of chromatography. 1989 Sep; 494(?):397-402. doi: 10.1016/s0378-4347(00)82694-8. [PMID: 2584339]
  • S K Puri, R S Hsu, I Ho, H B Lassman. Single dose safety, tolerance, and pharmacokinetics of HP 029 in healthy young men: a potential Alzheimer agent. Journal of clinical pharmacology. 1989 Mar; 29(3):278-84. doi: 10.1002/j.1552-4604.1989.tb03328.x. [PMID: 2723116]